ArticleJournal of neuro-oncology2026
The role of tumor-associated macrophages in the progression and recurrence of meningiomas.
Article in Journal of neuro-oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeMeningiomas are generally benign; however, they have high recurrence rates. The tumor microenvironment, particularly tumor-associated macrophages (TAMs) may play a role in tumor progression and recurrence. This study aimed to investigate the role of TAMs in tumor recurrence and patient survival in meningiomas, as well as their associations with clinicopathological and prognostic parameters.
methodsA total of 146 primary meningiomas were evaluated. The presence of TAMs was examined morphologically in hematoxylin-eosin stained tissue sections. The clinicopathological and prognostic data were analyzed. Recurrence-free survival (RFS), overall survival (OS), and disease-free survival (DFS) were evaluated.
resultsTAMs were detected in 30 of 146 (20.5%) meningiomas. Patients with TAM-positive meningiomas were younger than TAM-negative meningiomas (p = 0.04). There was no statistically significant association between the presence of TAM and gender, tumor size, tumor location, Simpson grade, or WHO grade (p > 0.05). Recurrences occurred more frequently and at an earlier stage in cases with TAM-positive meningiomas (p = 0.001). Cox regression analysis identified TAMs as an independent risk factor for recurrence. However, no significant association was observed between the presence of TAM and OS or DFS (p > 0.05).
conclusionThe presence of morphologically identified TAMs in meningiomas was found to be associated with tumor recurrence and shorter recurrence-free survival times. These findings suggest that a tumor microenvironment rich in morphologically identified TAMs may be associated with the risk of recurrence in meningiomas. However, morphological assessment of TAMs constitutes a major limitation of this study. Larger multicenter studies are needed to clarify the prognostic significance of TAMs in meningiomas.
Indexed as
Identifiers
42240744What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.